Discounted Cash Flow (DCF) Analysis Levered

Theradiag SA (ALTER.PA)

2.24 €

-0.06 (-2.61%)
All numbers are in Millions, Currency in USD
Stock DCF: -Infinity | 2.24 | overvalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 8.919.6410.4111.1212.2013.2014.2815.4516.7218.09
Revenue (%)
Operating Cash Flow -1.55-1.67-1.81-1.93-2.12-2.29-2.48-2.68-2.90-3.14
Operating Cash Flow (%)
Capital Expenditure -0.12-0.13-0.14-0.15-0.17-0.18-0.19-0.21-0.23-0.25
Capital Expenditure (%)
Free Cash Flow -1.67-1.80-1.95-2.08-2.29-2.47-2.67-2.89-3.13-3.39

Weighted Average Cost Of Capital

Share price $ 2.24
Beta -0.265
Diluted Shares Outstanding -
Cost of Debt
Tax Rate 29.64
After-tax Cost of Debt 3.36%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.189
Total Debt 1.84
Total Equity -
Total Capital 1.84
Debt Weighting 100.00
Equity Weighting 0.00
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 8.919.6410.4111.1212.2013.2014.2815.4516.7218.09
Operating Cash Flow -1.55-1.67-1.81-1.93-2.12-2.29-2.48-2.68-2.90-3.14
Capital Expenditure -0.12-0.13-0.14-0.15-0.17-0.18-0.19-0.21-0.23-0.25
Free Cash Flow -1.67-1.80-1.95-2.08-2.29-2.47-2.67-2.89-3.13-3.39
WACC
PV LFCF -2.39-2.50-2.62-2.74-2.87
SUM PV LFCF -13.13

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.36
Free cash flow (t + 1) -3.45
Terminal Value -253.99
Present Value of Terminal Value -215.30

Intrinsic Value

Enterprise Value -228.43
Net Debt -4.55
Equity Value -223.88
Shares Outstanding -
Equity Value Per Share -Infinity